Abiomed Price Target Increased to $35.00 by Analysts at Wunderlich (ABMD)
Wunderlich increased their price target on shares of Abiomed (NASDAQ:ABMD) from $29.00 to $35.00 in a research note issued on Friday, AnalystRatingsNetwork.com reports. The firm currently has a “buy” rating on the stock. Wunderlich’s target price points to a potential upside of 18.44% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Abiomed in a research note to investors on Monday, December 9th. They now have a $29.00 price target on the stock. Separately, analysts at Benchmark Co. reiterated a “buy” rating on shares of Abiomed in a research note to investors on Sunday, November 10th. They now have a $25.00 price target on the stock. Finally, analysts at Northland Capital Partners raised their price target on shares of Abiomed from $9.00 to $14.00 in a research note to investors on Thursday, November 7th. They now have an “underperform” rating on the stock. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. Abiomed has a consensus rating of “Hold” and an average target price of $26.60.
Abiomed (NASDAQ:ABMD) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.03 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.03. The company had revenue of $44.30 million for the quarter, compared to the consensus estimate of $43.75 million. During the same quarter in the previous year, the company posted $0.20 earnings per share. The company’s revenue for the quarter was up 18.4% on a year-over-year basis.
ABIOMED, Inc develops temporary and permanent cardiac support systems. The Company develops, manufactures and markets medical technologies designed to assist or replace the pumping function of the failing heart.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.